

Biofrontera Announces Appointment of Four New Supervisory Board Members

- **Elects Mark Reeth, John Borer III, Kevin Weber and Hansjörg Plaggemars**
- **Re-elects Jürgen Baumann and Ulrich Granzer**

Leverkusen, Germany, June 02, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced the appointment of four new members to its Supervisory Board. The four new members, Mark Reeth, John Borer III, Kevin Weber, and Hansjörg Plaggemars, all of them US citizens, were elected by shareholders during the Company's Annual Shareholder Meeting held on May 31, 2016 and will replace Andreas Fritsch, Ulrike Kluge, Alfred Neimke, and Prof. Bernd Wetzel, PhD as members of the board. In addition to the new appointments, Jürgen Baumann and Dr. Ulrich Granzer were re-elected to the Supervisory Board.

During its constitutional meeting held on June 01 the Supervisory Board has elected Ulrich Granzer as Chairman of the Supervisory Board and Jürgen Baumann as Vice-Chairman.

“We are pleased to announce the election of four new members, including three members living in the USA, with significant financial and commercialization experience, to the Supervisory Board, and would like to welcome back our two returning members,” stated Prof. Hermann Lübbert, Biofrontera's Chief Executive Officer. “The Board is comprised of a highly accomplished group of individuals with a wide breadth of expertise, and we look forward to leveraging their experience as Biofrontera continues to expand the global reach of Ameluz® to the U.S. with the recent FDA approval.”

The members of the Supervisory Board include:

Jürgen Baumann, is an independent management consultant and has served as the Chairman of the Supervisory Board since 2007. He has held senior roles at Schwarz Pharma AG and was previously an executive board member as well. He holds a Masters in Economics from the University of Wuppertal.

Ulrich Granzer, Ph.D., is the Founder and Managing Director of Granzer Regulatory Consulting & Services, and has served on the Supervisory Board since 2003. He was formerly Head of Regulatory Affairs at GlaxoSmithKline, BASF Pharma and Bayer Pharma, and has extensive expertise in the field of drug development. He holds his degree in pharmacy from Philipps University Marburg, in addition to a Ph.D. from University of Tübingen.

Mark Reeth, J.D., is an independent consultant specializing in trends in the pharmaceutical industry. He has more than 25 years of experience in a variety of senior management, legal and

News Release

compliance positions with U.S. based healthcare companies ranging from HMOs, pharmaceutical and medical device companies, such as NYLCare, Merck-Medco Managed Care, Bracco Diagnostics, Medicis Pharmaceuticals and Salix Pharmaceuticals. He holds a Doctor of Law degree (J.D.) and Master of Economics from Duke University.

John Borer III, J.D., is the Senior Managing Director and Head of Investment Banking at the Benchmark Company, LLC. He was formerly the CEO and Head of Investment Banking at Rodman & Renshaw, and has held senior positions at Pacific Business Credit and Barclays American Business Credit. He holds a Doctor of Law degree (J.D.) from Loyola Law School in Los Angeles.

Kevin Weber is the Chief Executive Officer of Paraffin International Inc. He has extensive experience in marketing and global operations and strategy, and has held senior roles at Depomed, Hyperion Therapeutics, and Medicis Pharmaceuticals. Kevin is also a board member of the American Academy of Pain Management Foundation and the American Chronic Pain Association. He holds a B.A. in Management and Marketing from Western Michigan University.

Hansjörg Plaggemars is a Member of the Management Board of Deutsche Balaton AG. He was formerly the Managing Director and Chief Financial Officer at CoCreate Software GmbH, KAMPA AG, Unister Holdings and Müller Holdings. Hansjörg is also a board member of Bolanta AG, Carus AG, Eurohaus Frankfurt AG, and Fidelitas Deutsche Industrie Holding AG, among others. He holds a degree in Business Administration from the University of Bamberg.

-Ends-

Enquiries, please contact: Biofrontera AG +49 (0) 214 87 63 2 0
Thomas Schaffer, Chief Financial Officer press@biofrontera.com

IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514
Jürgen Benker

IR UK: Seton Services +44(0) 20 7729 0805
Toni Vallen

IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui +1 646-536-7012 / 7035
PR: Kirsten Thomas +1 508-280-6592

About Biofrontera

Biofrontera Group (FSE: B8F, ISIN DE0006046113) **Biofrontera** is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz[®], a prescription drug which was initially approved and marketed in Europe and is now also approved in the US for the treatment of mild and moderate actinic keratosis, a

News Release

precursor to squamous cell carcinoma, with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now US approval for a medical device/drug it has developed itself.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.